Published in J Clin Oncol on June 01, 1997
Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer (GEST) | NCT00498225
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer | NCT00732082
Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer | NCT03959150
Pancreatic Surgery in Elderly Patients | NCT04893408
Pharmacotyping of Pancreatic Patient-derived Organoids | NCT05196334
Acelarin First Line Randomised Pancreatic Study (ACELARATE) | NCT03610100
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | NCT03717298
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Pancreatic cancer. Lancet (2004) 11.63
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov (2012) 4.30
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer (2010) 3.27
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 3.13
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol (2013) 3.11
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell (2014) 2.74
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
Biology and management of pancreatic cancer. Gut (2007) 2.53
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol (2014) 2.43
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell (2016) 2.32
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A (2007) 2.30
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer (2009) 2.13
PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Invest New Drugs (2014) 2.04
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol (2008) 2.04
MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene (2010) 1.99
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A (2013) 1.88
Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol (2008) 1.87
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer (2007) 1.87
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer (2009) 1.84
Current management of gallbladder carcinoma. Oncologist (2010) 1.83
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol (2009) 1.77
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer (2006) 1.71
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res (2008) 1.68
FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer (2000) 1.68
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res (2013) 1.67
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Targeting mTOR dependency in pancreatic cancer. Gut (2014) 1.65
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64
The paradox of response and survival in cancer therapeutics. Blood (2005) 1.63
Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS One (2013) 1.61
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther (2011) 1.61
New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol (2012) 1.57
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer (2003) 1.57
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer (2000) 1.56
High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer (2009) 1.55
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother (2012) 1.55
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev (2009) 1.54
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res (2011) 1.54
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol (2006) 1.53
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Photodynamic therapy for cancer of the pancreas. Gut (2002) 1.51
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer (2008) 1.50
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med (2016) 1.50
Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res (2008) 1.49
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer (2003) 1.48
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer (2005) 1.47
Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut (2005) 1.46
The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark. World J Surg (2011) 1.45
Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clin Cancer Res (2008) 1.44
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. J Natl Cancer Inst (2016) 1.44
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer (2006) 1.41
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res (2009) 1.41
Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One (2011) 1.39
Pharmacoeconomic effect of compliance with pharmacist's intervention based on cancer chemotherapy regimens: a cohort study. J Pharm Health Care Sci (2015) 1.39
Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol (2010) 1.38
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol (2009) 1.38
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene (2009) 1.37
Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer (2009) 1.36
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia (2010) 1.36
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer (2009) 1.36
Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets (2011) 1.36
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer (2010) 1.36
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 1.35
Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol (2013) 1.34
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther (2010) 1.34
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs (2005) 1.34
The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol (2011) 1.33
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol (2013) 1.33
Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res (2012) 1.33
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.32
Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res (1984) 86.56
Dissecting the regulatory circuitry of a eukaryotic genome. Cell (1998) 23.62
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med (2000) 18.12
Normal and mutant human beta-globin pre-mRNAs are faithfully and efficiently spliced in vitro. Cell (1984) 12.30
Pre-mRNA splicing. Annu Rev Genet (1986) 9.86
Human beta-globin pre-mRNA synthesized in vitro is accurately spliced in Xenopus oocyte nuclei. Cell (1983) 9.77
Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature (1994) 9.37
Excision of an intact intron as a novel lariat structure during pre-mRNA splicing in vitro. Cell (1984) 9.13
Transcription activation by the adenovirus E1a protein. Nature (1989) 9.08
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J (2000) 7.54
Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev (1989) 7.47
Definition of a novel promoter for the major adenovirus-associated virus mRNA. Cell (1980) 7.42
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Transcriptional activation of cloned human beta-globin genes by viral immediate-early gene products. Cell (1983) 7.22
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 7.02
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
Cloning and domain structure of the mammalian splicing factor U2AF. Nature (1992) 6.55
Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature (1994) 6.55
A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly. Cell (1988) 6.16
Mechanism of action of an acidic transcriptional activator in vitro. Cell (1991) 6.04
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins. Science (1995) 5.97
Facilitated binding of TATA-binding protein to nucleosomal DNA. Nature (1994) 5.95
Crow deaths as a sentinel surveillance system for West Nile virus in the northeastern United States, 1999. Emerg Infect Dis (2001) 5.83
Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest (1989) 5.71
The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J (2001) 5.69
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med (1992) 5.42
Sequence-specific RNA binding by the HIV-1 Rev protein. Nature (1989) 5.36
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor. Proc Natl Acad Sci U S A (1989) 5.11
Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 4.98
Binding of general transcription factor TFIIB to an acidic activating region. Nature (1991) 4.71
A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell (1990) 4.67
A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med (1990) 4.66
A mechanism for synergistic activation of a mammalian gene by GAL4 derivatives. Nature (1990) 4.57
An adenovirus E1a protein region required for transformation and transcriptional repression. Cell (1986) 4.56
An ordered pathway of snRNP binding during mammalian pre-mRNA splicing complex assembly. EMBO J (1987) 4.52
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colonic resection. Clin Nutr (2005) 4.43
HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell (1991) 4.43
cis and trans activation of globin gene transcription in transient assays. Proc Natl Acad Sci U S A (1983) 4.41
Transcription factor ATF interacts with the TATA factor to facilitate establishment of a preinitiation complex. Cell (1988) 4.15
An RNA processing activity that debranches RNA lariats. Science (1985) 4.14
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood (1998) 4.07
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature (1993) 3.97
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol (1991) 3.96
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst (1996) 3.95
A small-scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing. Gene Anal Tech (1989) 3.95
A cellular protein, activating transcription factor, activates transcription of multiple E1A-inducible adenovirus early promoters. Proc Natl Acad Sci U S A (1987) 3.91
Localization of pre-mRNA splicing in mammalian nuclei. Nature (1995) 3.88
Defining the clinically important difference in pain outcome measures. Pain (2000) 3.88
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
Functional domains of adenovirus type 5 E1a proteins. Cell (1987) 3.79
Pre-mRNA splicing alters mRNP composition: evidence for stable association of proteins at exon-exon junctions. Genes Dev (2000) 3.74
Functional recognition of the 3' splice site AG by the splicing factor U2AF35. Nature (1999) 3.72
GAL4 derivatives function alone and synergistically with mammalian activators in vitro. Cell (1988) 3.67
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
Specific and stable intron-factor interactions are established early during in vitro pre-mRNA splicing. Cell (1985) 3.59
Biochemical characterization of U2 snRNP auxiliary factor: an essential pre-mRNA splicing factor with a novel intranuclear distribution. EMBO J (1991) 3.54
Orthodontics in the general dental service of England and Wales: a critical assessment of standards. Br Dent J (1993) 3.52
Mammalian nuclei contain foci which are highly enriched in components of the pre-mRNA splicing machinery. EMBO J (1991) 3.49
Interaction of a common cellular transcription factor, ATF, with regulatory elements in both E1a- and cyclic AMP-inducible promoters. Proc Natl Acad Sci U S A (1988) 3.46
Expressing the human genome. Nature (2001) 3.45
A cellular transcription factor E4F1 interacts with an E1a-inducible enhancer and mediates constitutive enhancer function in vitro. EMBO J (1987) 3.45
Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ (1989) 3.32
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol (1997) 3.27
Cryptic branch point activation allows accurate in vitro splicing of human beta-globin intron mutants. Cell (1985) 3.25
Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med (1995) 3.25
SAGA is an essential in vivo target of the yeast acidic activator Gal4p. Genes Dev (2001) 3.23
Redundant roles for the TFIID and SAGA complexes in global transcription. Nature (2000) 3.21
Eukaryotic activators function during multiple steps of preinitiation complex assembly. Nature (1993) 3.16
Interaction of U2AF65 RS region with pre-mRNA branch point and promotion of base pairing with U2 snRNA [corrected]. Science (1996) 3.15
A family of immunologically related transcription factors that includes multiple forms of ATF and AP-1. Genes Dev (1988) 3.13
The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function. Genes Dev (1991) 3.08
HTLV-I Tax protein stimulation of DNA binding of bZIP proteins by enhancing dimerization. Science (1993) 3.05
Transcription activation in cells lacking TAFIIS. Nature (1996) 3.04
Sequence-specific binding of transfer RNA by glyceraldehyde-3-phosphate dehydrogenase. Science (1993) 3.03
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Evidence for interaction of different eukaryotic transcriptional activators with distinct cellular targets. Nature (1990) 3.03
Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science (2001) 3.03
Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med (1990) 3.01
A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature (1995) 2.98
A full genome search in multiple sclerosis. Nat Genet (1996) 2.96
How different eukaryotic transcriptional activators can cooperate promiscuously. Nature (1990) 2.91
Interaction between an acidic activator and transcription factor TFIIB is required for transcriptional activation. Nature (1993) 2.88
The SR protein family: pleiotropic functions in pre-mRNA splicing. Trends Biochem Sci (1996) 2.88
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med (1998) 2.85
Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit. Proc Natl Acad Sci U S A (1992) 2.82
Enhancement of TBP binding by activators and general transcription factors. Nature (1999) 2.76
Yeast TAFIIS in a multisubunit complex required for activated transcription. Nature (1994) 2.74
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol (2001) 2.73